Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313313 · ClinicalTrials.gov registry record · Phase 3
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 768
- Enrollment target
NCT00313313: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00313313 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 768 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313313, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 768 participants
- Enrollment target
Study Summary
The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
Primary Outcome
Mean change from baseline in A1C at Week 24, adjusted for baseline value.
Interventions
- DRUG Placebo
- DRUG Saxagliptin
- DRUG Glyburide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 768 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
What the finished NCT00313313 record still lists
NCT00313313 is an interventional study that assigns participants to a tested intervention. The registered 768 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00313313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00313313 about?
NCT00313313 is a clinical study titled "A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas". The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
What is the current status of trial NCT00313313?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 768 participants. The study started on 2006-04. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00313313?
The interventions under investigation include: Placebo (DRUG), Saxagliptin (DRUG), Glyburide (DRUG).
Who is sponsoring clinical trial NCT00313313?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00313313's enrollment target sits among peer trials
768 445th of 2000 higher than 1,556 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
- NCT05660525 · 768 participants · NA
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
- NCT06324357 · 768 participants · Phase 1
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia